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Abstract 
Background: Protoporphyrin IX (PpIX) is an endogenous fluorescence that is 
accumulated in cancer cells treated with the heme precursor 5-aminolevulinic 
acid (5-ALA). The cancer-specific fluorescence of PpIX is used to distinguish 
tumor from normal tissue, which has proven clinically useful during fluorescence-
image guided surgery. This study sought to investigate whether modulation of 
oncogenic Ras/MEK pathway mediates PpIX accumulation in vitro and in vivo. 
Methods: For in vitro studies, human breast, lung and prostate cancer cells were 
treated with or without the MEK inhibitor (U0126) for 20 hours, followed with 5-
ALA for 5 hours. The cells were lysed, and the PpIX fluorescence accumulated in 
the cells was measured with a microplate fluorescence reader (λex 405 nm; 
λem635 nm). For in vivo studies, the 4T1 mouse breast cancer cells were 
injected into the right hind flank of 8 week-old Balb/c female mice. U0126 (50 
µM/Kg) was injected intratumourally to 4T1 breast tumors for 5/8 h followed by 5-
ALA injection. Mice bearing 4T1 breast tumors were also injected 
intraperitoneally with U0126 for 5 or 8. Furthermore, similar experiments were 
conducted using a HRAS transgenic mice, which develop spontaneous 
mammary tumors within 3 months old. Results: In vitro, MEK inhibition increases 
PpIX fluorescence in human cancer cell lines, but not in normal cell lines. The 
promotion of PpIX fluorescence by MEK inhibition was most commonly observed 
among human breast cancer cells. In vivo, PpIX accumulation was observed 
significantly more in the tumors from mice treated with U0126 and 5-ALA (2-3 
fold) than those from mice with vehicle control (DMSO/saline) and 5-ALA. 
Conclusions: In vitro and in vivo treatment of the MEK inhibitor significantly 
increases the accumulation of PpIX fluorescence in cancer cells which may 
contribute to improved efficacy of FGS in clinical settings. 
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Chapter 1: Introduction 
1.1 Therapeutic strategies for cancer treatment 
Cancer is a major public health problem across the globe. In the next two 
decades the number of new cancer cases will rise to 22 million worldwide 
(Siegel, Miller, and Jemal 2015). Fortunately, the cancer-associated mortality rate 
has declined as a result of improved cancer awareness, screening, prevention 
and clinical treatments. According to the Canadian Cancer Society Statistics 
Report (2015), as a result of cancer prevention efforts over 126,000 deaths have 
been avoided since 1988, when the cancer mortality rate peaked in Canada. 
There was an increase in survival rate from 56 % to 63 % between 1992-94 and 
2006-08, considering all cancers combined in Canada (“Canadian Cancer 
Society,” 2016).These statistics show that progress is being made to treat cancer 
and extend the expected lifespan of cancer patients, but much work still remains. 
There are several treatment methods that play a major role in cancer control, 
such as chemotherapy, radiotherapy and surgical removal of solid tumours; each 
of these options have some advantages and some disadvantages for the patient 
during their cancer treatment. Generally, cancer therapies are selected by the 
oncological team based on the type or stage of the cancer and the patient’s 
health status (“Canadian Cancer Society,” 2016).  
Chemotherapy is one approach for cancer treatment that targets cancer 
cells with pharmaceutical drugs. Traditional chemotherapeutic agents are toxic 
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and target cancer cell proliferation to effectively poison cancer cells that divide 
rapidly, which in return would also damage normal cells that divide rapidly 
including: bone marrow, digestive tract and hair follicles (Raguz and Yagüe 
2008). Chemotherapy may be given as a single treatment or it may be given 
along with other anticancer therapies. One major advantage of chemotherapy is 
wide distribution of the drug through the whole body, with the potential to target 
cancer cells that have metastasized away from the primary tumour site. 
Chemotherapeutic drugs are sometimes combined to manage tumour cell 
populations that have heterogeneous features, with the intent of dose reduction 
for single agents to reduce the side-effects (Gamelin et al. 2008). Newer 
chemotherapeutic combinations include more targeted drugs that are directed to 
a specific feature of the cancer cell, such as a membrane bound receptors or cell 
surface antigens, as opposed to the cell replication machinery. For instance, 
specific antigens or receptors expressed on tumour cells can be used to develop 
targeted prodrugs by conjugating anti-cancer drugs to monoclonal antibodies or 
ligands. These prodrugs can be targeted selectively to tumours without harming 
normal cells and release the more toxic drug inside or outside the tumour cell, 
leading to cancer cell death (Singh, Palombo, and Sinko 2008). Targeted 
therapies are generally more selective and less toxic than traditional 
chemotherapy, primarily because the mechanisms of targeted therapies differ 
from the more traditional cytotoxic chemotherapies (Gerber 2008). 
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Though chemotherapy has been proven to be one of the most effective 
cancer treatment methods for several types of cancer, it comes with various short 
and long-term side effects. According to the Canadian Cancer Society symptoms 
such as nausea, vomiting, loss of appetite, constipation or diarrhea are common 
short-term side effects experienced by chemotherapy patients (“Canadian 
Cancer Society,” 2015). In the long-term, the first round of chemotherapy might 
not be curative due to the emergence of recurrent disease. The quality of life 
after chemotherapy is another critical factor for a patient’s health. Side effects 
related to chemotherapy may appear months after treatment has ended, with 
heart or kidney problems and lung tissue damage as some of the common long-
term side effects (“Canadian Cancer Statistics” 2015). For instance, the survivors 
of breast cancer are at significantly increased risk of death caused by 
cardiovascular complications, including heart failure, hypertension and 
arrhythmias (Bodai and Tuso 2015). Traditional chemotherapies also have 
mutagenic potential, which is not a particularly good choice for childhood cancer 
patients, since the treatment comes with an increased risk of secondary cancers 
due to chemotherapy (Maniar et al. 1991). For each patient, the choice of 
chemotherapy is weighed against the benefits and risks, in accordance with the 
patient’s health, age and prognosis.    
Radiation therapy (radiotherapy) is another method that delivers cancer-
killing doses of ionizing radiation precisely to one particular location. Unlike 
chemotherapy, the damage to the normal cells in the body is significantly 
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reduced with the use of localized radiation. Radiotherapy alone may be used for 
treatment of small tumours and is also useful to shrink large mass tumours 
before surgery (Silva et al. 2015). Radiation therapy is usually synergistic 
with chemotherapy and has been used in susceptible cancers before, during, and 
after chemotherapy (Ragaz et al. 1997). However, radiotherapy and 
chemotherapy usually require a lengthy treatment time of nearly 5–6 weeks. 
Several factors that influence a patient’s choice for surgical interventions instead 
of this long course of treatment include advanced age, a long travel distance to 
the hospital, and socioeconomic status (Blinman et al. 2013). In addition, cancer 
cells within a tumour are heterogeneous and the success of chemotherapy or 
radiotherapy is based on cancer as a homogeneous disease with consistent 
features across all tumour cells (Sun and Yu 2015). Resection of the tumour by 
surgery is the primary treatment for most solid tumours, and if the tumour is 
removed completely, then the patient no longer has cancer and is ultimately 
“cured”. Therefore, surgery is a useful strategy to overcome the challenges of 
tumour heterogeneity. Furthermore, since tumour resection removes as many 
cancer cells as possible from the body, it minimizes the population that might 
require further treatment such as chemotherapy or radiotherapy (Nguyen and 
Tsien 2013).  
1.1.1 Fluorescence-Guided Surgery 
Surgical removal of solid tumour masses is advantageous for cancer 
patients, but complete removal of the tumour mass is a challenge.  The presence 
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of residual tumour cells in the target tissue post-surgery is generally associated 
with increased local recurrence of tumour and a decreased overall survival rate 
(Frankel et al. 2013; Nguyen and Tsien 2013).The other primary goal of the 
skilled surgeon is to retain organ function. In the case of brain tumours, for 
example, the border between tumour and normal tissue may not be well-defined 
and the surgeon is challenged to optimize tumour removal while retaining as 
much normal brain tissue as possible, to optimize the patient’s quality of life post-
surgery. Fluorescence-guided surgery (FGS) is as a medical imaging technique 
that facilitates the removal of solid tumours and maximizes the precision of 
tumour resections. FGS proceeds in real-time during the operation with 
simultaneous illumination of the surgical region to excite a fluorophore molecule 
that is selectively accumulated in the tumour tissue, while recording the 
fluorescence emissions through specialized imaging filters or lenses (Mondal et 
al. 2014). Although cure is the primary goal of cancer surgery, preservation of 
important structures during surgery such as nerves, blood vessels, ureters and 
bile ducts is equally crucial in achieving optimal outcome (Nguyen and Tsien 
2013). Moreover, chronic post-surgical pain caused by nerve damage may lead 
to loss of function and certainly reduces the patient’s quality of life (Burke and 
Shorten 2009). Therefore, it is important for a surgeon to able to see structures 
for an accurate resection and prevent damage to normal tissues and organs; for 
this purpose, FGS is a valuable strategy to support both desired outcomes of 
tumour surgery. 
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1.1.2 Properties of Fluorophores 
  The full potential of FGS for optimal tumour removal relies on the chemical 
properties of the contrast molecules used to discriminate the tumour from normal 
tissues (Allison 2015). As a chemical class, fluorophores have the unique 
property of energy absorption leading to electron excitement, followed by 
electron relaxation and energy release in the form of light. Generally, the light 
emission is of lower energy (longer) wavelength than the excitation wavelength, 
which represents a shift on the visible colour spectrum (Allison 2015).  Figure 1 
illustrates the pattern of light absorption, electron responses in the fluorophore 
and the wavelength output.  Due to exposure of excitation light, the electron of a 
specific fluorophore reaches a higher energy level or electron shell (e.g. S1 or 
S2) above the ground state (S0). The excited electrons primarily relax at S1 level 
and then return to their S0, where energy is released as fluorescence (Lakowicz 
2006). The time interval that fluorophore electrons stay in the excited state before 
returning to the ground state is known as the fluorescence lifetime, while the 
number of photons emitted as a proportion of the photons absorbed is known as 
the quantum yield of the fluorophore. The quantum yield can be affected by the 
environment of the fluorophore. This is particularly important for FGS applications 
when the fluorophore is located under the tissue surface, since the excitation 
light must travel through tissues to reach the fluorophore. Fluorescence 
emissions can also be influenced by several factors, such as scattering, 
absorption, angle of light and tissue surface, and only some of the emissions are 
on the visible spectrum and detectable by the human eye (Lakowicz 2006). The 
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most important intrinsic fluorophore characteristics to consider for FGS are the 
fluorescence lifetime, excitation and emission spectra and quantum yield, to 
achieve bright, tumour-specific fluorescence that is informative for the surgeon in 
real-time.    
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Figure 1: Principle of fluorescence emission  
S0 represent the singlet ground and S1 and S2 are the first and second 
electronic levels. The dashed lines at each electronic level represent the 
vibrational energy levels. With Permission” form springer science (Lakowicz 
2006) 
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1.1.3 Basic features of Fluorescence-guided surgical practice  
There are several factors that require consideration when using 
fluorescence detection in the operating room or other clinical settings:  the 
selectivity of a drug to target tumour and not normal tissue, the quantum yield of 
the fluorophore, representing a significant difference in fluorescence emissions 
between tumour and normal tissue and the ease of integration into surgical 
practice (Sevick-Muraca & Rasmussen,2014). Fluorescence detection of tumour 
margins is meant to facilitate the surgical process without introducing too much 
additional complexity to the operating procedures (Gioux, Choi, and Frangioni 
2010).  For the patient, the administered drug should be easily administered and 
have amphipathic properties in order to travel in the bloodstream and reach the 
tumour blood supply, it should be safe and not harmful for other organs or normal 
tissues. Ideally, the drug should also have a short life time in the body with rapid 
excretion or metabolism after administration (Allison 2015). 
 
1.1.4 Fluorescence contrast agents 
FGS uses fluorophore in tissue, both exogenous and endogenous, to 
distinguish between normal and abnormal tissues. Fluorophores used in surgical 
applications can be divided into two main groups. They are either endogenous to 
tissues, or they can accumulate following administration of an exogenous 
compound.(Allison 2015). 
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1.1.4.1   Exogenous fluorescence 
 
Exogenously administered fluorescent contrast agents generally have 
higher fluorescence yield compare to endogenous fluorescent agents, such that 
real-time imaging and detection is facilitated (Ramanujam, 2000). 
There are two groups of fluorescent molecules applied to surgical procedures for 
solid tumours, non-specific and specific agents.   
1.1.4.1.1   Non-specific fluorescence contrast agents:  
These fluorophores are not tumour specific, but are designed to target 
rapidly proliferating tissues such as tumours or wounds, and therefore can be 
beneficial for FGS in certain situations. These agents are available commercially 
and are considered safe for clinical use. Some well-known agents in this category 
are Indocyanine Green, Fluorescein, and Lugol’s Iodine (Table 1). 
1.1.4.1.2   Tumour-specific fluorescence contrast agents:  
These agents are more specifically concentrated in tumours relative to 
normal tissues; however the mechanism behind this phenomenon still is 
unknown (Huang, 2005,Matsui et al., 2010). Some of the well-known agents in 
this group are Photofrin, Foscan, Verteporfin (Table 2). 
1.1.4.2   Endogenous fluorescence 
Endogenous metabolites of the human body have fluorescent properties; natural 
emission of light by these structure is called autofluorescence. The most 
commonly observed autofluorescent molecules are: Flavin Adenine Dinucleotide 
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(FAD), porphyrins and intracellular Nicotinamide Adenine Dinucleotide (NADH) 
(Table 3). The major benefit of using autofluorescence contrast is that the patient 
does not need to take drugs, which prevents complications such as toxic 
accumulation in the kidneys and liver, or allergic reactions. However, weak 
quantum yield and scarcity of endogenous fluorophores limit their use in FGS 
imaging applications. In addition, it is difficult to use endogenous contrast in a 
specific manner such as distinguishing tumour from normal tissue. Due to these 
limitations, researchers have developed techniques to enhance endogenous 
fluorescence (Marcu et al.2004).  
In exogenously induced fluorescence, accumulation of fluorescent molecules in 
tissue is either from administration of the fluorophore itself or from administration 
of a compound that acts as a precursor to a fluorescent molecule in a cellular 
pathway (Borisova et al. 2013). 
δ-Aminolevulinic acid (5-ALA) is an indirect photosentisizer which promote 
the production of PpIX in the cells and has attracted a great attention from all 
over the world. Since 2007 5-ALA has been approved for clinical use in Europe. 
In Canada, USA, and Australia it has been tested for clinical trials. Exogenous 
administration of ALA overrides the heme biosynthetic pathway, resulting in 
increased production and accumulation of a naturally occurring fluorescent 
porphyrin IX (PpIX). By using proper fluorescence detection instrumentation the 
clinician or researchers are able to detect PpIX. 5-ALA can be used for both FGR 
which allow for fluorescence and Photodynamic therapy (PDT). When 
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photosensitizers are exposed to a specific wavelength of light, they produce 
singlet oxygen that kills tumour cells (Collaud et al. 2004).  
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Table 1: Non-specific fluorescence contrast agents  
Name Chemical Structure Application Excitation 
(nm) 
Emission 
(nm) 
Reference  
Indocyanine 
green 
 
lymph node status with malignant 
tumours 
600-900 750-950 (Hirche et al. 
2010)(Kraft and Ho 
2014) 
Fluorescein 
 
label and track cells of interest 494 512 (Moore  and 
Peyton1948)  
Violet 
Acetate 
 
Nissl staining of brain paraffin and 
spinal cord section. Stain RNA blue, 
highlight important structural 
features of neurons  
540 625 (McDaniel and 
Tucker 1992) 
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Table 2: Tumour-specific fluorescence contrast agents 
Name 
 
Chemical Structure Application Excitation 
(nm) 
Emission 
(nm) 
Reference  
Photofrin 
 
Bladder cancer, esophageal cancer, on-
small cell lung cancer 
615 500 (Wezgowiec et al. 
2013) 
Foscan  
 
Squamous cell carcinoma of the head 
and neck 
420 652 (de Visscher et al. 
2013) 
Verteporfin 
 
Abnormal blood vessels 436 690 (Shao et al. 2015) 
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Table 3: Endogenous fluorescence contrast agents  
Name 
 
Chemical Structure Application Excitation 
(nm) 
Emission 
(nm) 
Reference  
Flavin Adenine 
Dinucleotide (FAD) 
 
Monitor disease 
progression or aid in 
diagnosis.  
450  515-520  (Sivabalan et al, 
2010) 
Porphyrins 
 
Differentiate tumour from 
normal tissue during the 
surgery 
405 635 (Peng et al. 
1997) 
Nicotinamide Adenine 
Dinucleotide (NADH) 
 
Live imaging of different 
organs, Commonly used 
in neurosurgery to label 
normal from tumour 
tishhu 
340  460 (Pogue et al. 
2010) 
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1.2  PpIX is an intermediate of the heme biosynthesis pathway 
Heme is an essential molecule synthesized in all cells of human, animals, 
fungi, plants and some bacteria. The heme biosynthesis pathway consists of 
eight steps across different cellular compartments (Figure 2). In eukaryotes, the 
biosynthesis pathway is located partly in the mitochondria and partly in the 
cytosol. The first step of the heme biosynthesis pathway is the synthesis of 5-
ALA from the amino acid glycine and succinyl CoA by ALA-synthase (ALAS) on 
the inner mitochondrial membrane. In the second step, 5-ALA is transferred to 
the cytosol where porphobilinogen (PBG) will be formed when 2 molecules of 
5-ALA are condensed by metalloenzyme 5-aminolevulinate dehydrase (ALAD), 
also known as porphobilinogen synthase (PBG-D) (Pogue et al. 2010).  In the 
third step, PBGs are combined by porphobilinogen deaminase and 
uroporphyrinogen III co-synthase in the cytosol. Next, hydroxymethylbilane 
(HMB) is generated by the condensation of 4 molecules of PBG (Bung et al. 
2014) ; this step is catalyzed by porphobilinogendeaminase (PBGD), which is 
also known as hydroxymethylbilane synthase (HMBS). Porphobilinogen 
molecules lose their amino acids leading to the formation of a linear tetrapyrrole, 
which then cyclizes to form cyclic uroporphyrinogen III by uroporphyrinogen III 
synthase (UROS). Decarboxylation of uroporphyrinogen III by 
uroporphyrinogen III decarboxylase (UROD) leads to coproporphyrinogen III. 
Further decarboxylation and oxidation occurs by copropophyrinogem oxidase in 
the mitochondria to form PpIX. The final step in heme synthesis involves insertion 
of an iron (II) ion into PpIX by ferrochelatase to produce heme. In contrast to 
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PpIX, heme has no fluorescence or photosensitizing activity (Sandanaraj et al. 
2010), while PpIX has received a lot of attention since it has intense fluorescent 
properties useful for tumour-selective FGS (Stummer et al. 2000). 
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Figure 2: Heme biosynthesis pathway  
5-ALA is a non-fluorescing substance and precursor of heme biosynthesis. 
Exogenous administration of 5-ALA leads to accumulation of the strongly 
fluorescing PpIX in tumour tissue. Several factors and enzymes are involved in this 
complex pathway.  
ALA-D: ALA dehydratase; ALA-S: ALA synthetase; Coprogen III: 
coproporphyrinogen III; CPO: coproporphyrinogen oxidase; FCH: ferrochelatase; 
HMB: hydroxymethylbilane, PBG-D: porphobilinogren deaminase; protogen III: 
protoporphyrinogen; PPO: protoporphyrinogen oxidase; Urogen III: uropor-
phyrinogen III; UCS: uroporphyrinogen cosynthase, UGD: uroporphyrinogen 
decarboxylase. 
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1.2.1 5-Aminolevulinic Acid (5-ALA) for cancer detection and therapy 
Since 1992, recognition of 5-ALA induced PpIX accumulation as a 
common feature of epithelial tumours has led to the development of specific 
instrumentation to detect PpIX with endoscopic and open surgery FGS methods 
(Valdés et al. 2011). For example, 5-ALA has been used as a biomarker for 
distinguishing normal tissue from tumour tissue with success in cases of high 
grade glioblastoma and bladder cancer (Lau et al. 2015). For human use, 5-ALA 
is dissolved in water and administered orally within 1 h prior to visualization 
(Morimoto et al. 2014). However, in pre-clinical studies involving animal models, 
administration of the drug via injection is the ideal route, since 5-ALA has an 
unpleasant taste and is difficult for animals to ingest (Stummer et al. 1998; Lin et 
al. 2001).   
The mechanism underlying the selective accumulation of PpIX upon 5-
ALA administration in tumours is still not fully understood. The net cellular 
accumulation of PpIX stimulated by 5-ALA treatment is dependent on several 
factors such as 5-ALA uptake, the rate of PpIX synthesis, the rate of iron 
incorporation to produce non-fluorescent heme and the rate of PpIX efflux 
through different transporters to the cell microenvironment (Kobuchi et al. 2012). 
Several studies have indicated that the elimination of PpIX from cells is carried 
out by the ATP-binding cassette (ABC) transporter G2 (ABCG2), which is a multi-
drug resistance-associated protein (Fujita et al. 2016; Imai et al. 2009; 
Yamamoto et al. 2013). Furthermore, tumours with a high metabolic rate have a 
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decrease in the cellular iron supply which reduces PpIX conversion to heme, 
leading to PpIX accumulation (Pichlmeier et al. 2008; Zhou et al. 2005). For FGS, 
cellular factors influencing the net balance of rapid PpIX accumulation are most 
significant to identify tumour foci. 
1.2.2 Clinical applications of 5-ALA for FGS 
The dosing of 5-ALA to induce PpIX is a simple procedure for the cancer 
patient.  In brief, a few h before the surgery, 5-ALA, 20 mg/kg per body weight 
(BW) is administered orally to the patient, which leads to PpIX accumulation 
selectively in their solid tumours (Loh et al. 1993). By using violet-blue light with 
excitation of 405 nm, tumours can be visualized in real time by emitted 
fluorescence at 635 nm, turning the tumour tissue into a red-pink color relative to 
the blue illumination field of normal tissues. This high colour contrast assists the 
surgeons with fluorescent guidance during the tumour resection (Stummer et al. 
2000). 5-ALA derivatives have been used to stimulate the PpIX-fluorescence as 
a surgical biomarker for several types of cancer in clinics all around the world. 
The European Union allows photodynamic detection of cancer of the bladder, 
brain, and skin (Millon et al.2010). For instance, FGS approach was validated by 
pathologist, in terms of tumour/normal tissue boundaries in malignant glioma 
resection using 5-ALA stimulated PpIX for FGS (Pichlmeier et al. 2008). In the 
United States, 5-ALA has been applied in clinical studies and the FDA has 
approved it for use on skin cancer (Millon et al.2010). The potential for 5-ALA in 
FGS is great; however, global use to improve patient outcomes is hampered by 
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several factors, primarily related to variation in the net PpIX accumulation profile 
of different tumour classes (Silva et al. 2015). 
1.2.3 Limitations of 5-ALA use for FGS applications 
Although 5-ALA allows surgeons to more accurately distinguish tumour 
tissue from normal tissue, there are some limitations to using 5-ALA as a single 
contrast stimulus. Even though significant success was observed for malignant 
glioma resections, inconsistencies in fluorescence contrast using 5-ALA have 
also been reported (Stummer et al. 2000). For example, some tumours do not 
fluoresce in patients after treatment with 5-ALA (Moiyadi, Syed, and Srivastava 
2014). One hypothesis for a lack of consistent response might relate to the 
cancer subtype, with 5-ALA induced PpIX fluorescence being more consistent 
and reliable in high-grade glioblastoma, while in low grade glioblastoma (GBM I 
and II) there is no significant PpIX fluorescence accumulation and therefore 5-
ALA cannot be used as a biomarker for fluorescence assisted surgery (S. Zhao 
et al. 2013). Furthermore, the fluorescence quality plays a major role in surgical 
outcomes. According to a study reporting two types of fluorescence: dense and 
bright fluorescence vs unclear fluorescence. Unclear fluorescence leads to the 
potential for unidentified tumour tissue that is missed during FGS (Metildi et al. 
2012). In terms of short-term disadvantages, one other outcome of 5-ALA loading 
during the surgery is short term photosensitivity in the skin and the eyes may 
become very sensitive to light (Inoue et al. 2016). Therefore, it is very important 
to protect the eyes and skin during this time and avoid bright lights and direct 
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sunlight that could lead to skin irritation or eye damage (“Photodynamic Therapy” 
2016). To overcome these limitations, experimental therapeutic research to 
enhance the sensitivity and specificity of PpIX-mediated FGS for tumour 
detection could lead to better patient outcomes with more complete resections 
and reduced side effects (Valdés et al. 2011; Y. Zhao and Adjei 2014). For this 
purpose, a better understanding of the mechanism of tumour PpIX accumulation 
is warranted. Since PpIX accumulation is a generalized property of many tumour 
types such as skin, bladder and brain. One approach is to investigate 
associations with other commonly disrupted signalling pathways in a majority of 
human cancers. One prominent example is the high frequency of activating 
mutations of the Ras intracellular signalling protein, a pro-oncogenic member of 
the Mitogen-activated protein kinase cascade that is found in approximately 30% 
of all human cancers (Roberts and Der 2007). 
1.3  Mitogen-activated protein kinases (MAPK) signalling pathway 
1.3.1 MAPK Protein Kinase Family 
 Kinase is an enzyme that catalyzes the transfer of phosphate groups from 
high energy molecule (such as ATP) to specific substrates. This process is 
known as phosphorylation. MAPKs are a family of kinases that participate in 
signal transduction pathways responsible for regulating gene expression, motility, 
metabolism, survival, apoptosis and differentiation (Chakraborty et al. 2013). 
Some of the kinases that comprise the MAPKs family include the 
serine/threonine protein kinase (Raf), mitogen-activated protein/extracellular 
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signal-regulated kinase (MEK), the extracellular signal regulated kinases (ERK) 
kinase family, c-Jun amino (N)-terminal kinases 1/2/3 (JNK1/2/3), and the p38 
map kinase family isoforms (α,β,ʎ,δ) (Montagut and Settleman 2009)(Figure 3). 
1.3.2   MAPK signaling pathway 
Activation of the MAPK signalling pathway is via signal initiation which 
depends on several factors such as growth factors, hormones, and cytokines and 
through the Ras and Rho families of small GTPases (Roberts and Der 2007). 
Three MAPK families have been distinguished: Jun kinase (JNK/SAPK), p38 
MAPK and extracellular signal-regulated kinase (ERK)(W. Zhang and Liu 2002). 
1.3.2.1   JNK and p38 signaling pathway 
The JNK family of MAPKs, which are known as stress activated protein 
kinases, are activated by stress stimuli such as environmental stress, radiation 
and growth factors. Members of p38 family of MAPKs are primarily activated by 
stress stimuli, but also during engagement of various cytokine receptors by their 
ligands. The function of p38 kinases is required for various activities, including 
signal transduction mediator and regulation of apoptosis and cell cycle arrest, cell 
differentiation, as well as cytokine production and inflammation (Dhillon et al. 
2007). 
1.3.2.2   ERK 1 and MEK1/2 signalling pathway 
Stimuli such as growth factors, cytokines and extracellular mitogens 
activates MAPK signalling cascades. Upon activation, MAPKs send signals to 
several intracellular targets and leads to binding of diverse collection of growth 
24 
 
factors receptors including epidermal growth factor receptor (EGFR). Following 
activation, MAPKs recruit guanine nucleotide exchange factors (GEFs) to the 
plasma membrane where it activates RAS GTPases by conversion of GDP-
bound RAS to active GTP-bound RAS. RAF kinases are activated and recruited 
to the membrane by activated RAS. Subsequently, RAF activates MEK kinases. 
MEK1/2 are dual specificity kinases that catalyse the phosphorylation events of 
ERK1/2 at both tyrosine and threonine resides. ERK1/2 are the only known 
physiological substrate of MEK1/2. When ERK is phosphorylated it can 
translocate to the nucleus where it generates multiple phosphorylation and 
activates numerous transcription factors and other kinases. Activated ERK1/2 
catalyse many events such as mitosis, cell differentiation, motility, metabolism, 
angiogenesis and apoptosis. 
Mutation in components of the ERK signalling cascade are seen in 
approximately 30 % of all human cancers (Cargnello and Roux 2011).  Extensive 
research has established that MEK1 and MEK2 play critical roles and contribute 
to tumourigenesis (Dhillon et al. 2007). In addition, proto-oncogene B-Raf (BRAF) 
mutations have been recognized in a narrower range of malignancies 
(Oikonomou et al. 2014). Therefore, the MEK pathway is widely studied and 
various drugs targeting this pathway have been generated for cancer therapy, as 
a strategy to inhibit autocrine signalling pathways that support tumour cell 
survival (Y. Zhao and Adjei 2014). 
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Figure 3: Mitogen-activated protein kinase (MAPK) signaling pathways. 
MAPK signaling pathways are activated by extracellular or intracellular 
stimuli, upon which they activate other intracellular signaling pathways. Activated 
MAPKs phosphorylate numerous substrate proteins including transcription 
factors, resulting in regulation of a variety of cellular activities including cell 
proliferation, differentiation, migration, and apoptosis. The mammalian MAPK 
family includes ERK, p38, and JNK. In the ERK signaling pathway, ERK1/2 is 
activated by MEK1/2, which is activated by Raf. Raf is activated by the Ras 
GTPase, whose activation is induced by RTKs such as the epidermal growth 
factor receptor.   
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1.3.3  Pharmacological inhibitors for MEKs 
Since MEK1 and MEK2 have crucial roles in tumourigenesis, including 
inhibition of apoptosis and promotion of cellular invasion and proliferation, 
several specific and highly potent MEK1/2 combination inhibitors have been 
developed, some of which are already assessed in clinical studies. PD98059 and 
U0126 were the first MEK inhibitors developed and potently inhibit MEK1 and 
MEK 2 in a variety of cell types. PD098059 inhibits the activity of MEK1/2 in vitro 
and in vivo by stabilizing the inactive conformation of MEK, and as a result, 
inhibits cell proliferation and induces apoptosis in solid tumours (Moon et al. 
2007). U0126 is a small, non-ATP competitive molecule that appears to inhibit 
the activation of MEK through Raf, and as a result, also inhibits the downstream 
phosphorylation of ERK  (Duncia et al. 1998). Through inhibition of MEK, U0126 
blocks the production of various cytokines involved in inflammatory responses. 
For the purpose of cancer therapy, U0126 administration triggers cell cycle 
arrest, increased apoptosis, reduced migration potential, leading to an overall 
decreased tumourigenicity of cancer cells (Hawkins et al. 2008; Duncia et al. 
1998). Cancer therapeutic has changed from non-specific cytotoxic agents to 
selective, mechanism based treatment in the past decades. MEK inhibitors, in 
addition to their primary anti-cancer effects, have the potential to sensitize cancer 
cells to other drugs (Vanneman and Dranoff 2012). 
Acquired drug resistance in tumour cells is one of the main problems of 
chemotherapy. Tumours are heterogeneous and resistance to drugs is based on 
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several factors, including inhibition of apoptosis, DNA repair and increased efflux 
of anticancer agents out of the cells by ATP-binding cassette (ABC) transporters, 
also known as Multi-drug resistance proteins(MRP) (Gottesman, Fojo, and Bates 
2002). Mutation of the MAPK pathway has been shown to be associated with 
overexpression of MRP in cancer cells (McCubrey et al. 2007a). These results 
suggest that MAPK pathway and drug resistance may interact with each other in 
cancer cells. This association of cancer cells having both features could be 
mechanistically related or unrelated, since they are both common features of 
cancer cells However, the mechanism and involvement of the downstream MAPK 
pathway in mediating the ABC proteins expression remains unclear (Hoffmann et 
al. 2011; Chakraborty et al. 2013). 
1.3.4 Clinical development of next-generation MEK inhibitors  
The pharmacological structure of U0126 and PD98059, which were the 
first MEK kinase inhibitors developed. None of these compounds was moved to 
clinical trials due to their pharmaceutical limitations such as low bioavailability 
and distribution.  
However, studies show that they are valuable tools for academic research 
to assist in understanding the MEK pathway. There are several other MEK 
inhibitors that are currently being tested in clinical trials.  
The first MEK inhibitor that reached the clinical trial phase was a small-
molecule CI-1040(Pfizer) which showed inhibition of tumour growth in phase I 
trial. However, due to the poor bioavailability of the drug and inconsistency in 
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phase II clinical trial the development of CI-1040 (Pfizer) was terminated. 
Selumetinib (AZD6244) is another MEK inhibitor. It is highly selective for MEK1 
and MEK2 and is the most widely studied MEK inhibitor in the clinic. At phase II 
study, anti-tumour activity is observed. However, there were no significant 
progression-free-survival difference observed. Furthermore, studies show that 
Selumetinib has modest anti-tumour affect as a single agent and failed to show 
significant clinical activity so far. To date, there are clinical studies with 
combination of Selumetinib and other chemotherapies drug such as carboplatin, 
temsirolimus, docetaxel and PI3K inhibitors to expand the efficacy of Selumetinib. 
In 2013, Trametinib (GSK) an orally bioavailable MEK1/2 inhibitor got FDA 
approval for metastatic melanoma with BRAF (proto-oncogene B-Raf) mutation. 
Trametinib prevents RAF-dependent MEK phosphorylation and activation by 
binding to un-phosphorylated MEK1/2 (Y. Zhao and Adjei 2014; Montagut and 
Settleman 2009). Trametinib is currently being studied for other types of cancer.  
1.4 Study rationales 
  The purpose of this experimental investigation is to combine two areas of 
research in cancer therapeutics, with the goal to enhance PpIX fluorescence 
specifically in cancer cells with a combination of 5-ALA and MEK enzyme 
inhibitors. Previously, Hirasawa et al. made a novel observation on the interaction 
between the heme biosynthesis pathway and the oncogenic Ras/MEK pathway 
(Ema Yoshioka, Ken Hirasawa 2014).  It was noted in a cancer cell culture model 
that MEK inhibition promotes PpIX accumulation in combination with 5-ALA 
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treatment and the result showed the higher PpIX accumulation with U0126 
compare to PD98059 (Ema Yoshioka, Ken Hirasawa 2014). So far, there are 
very few compounds reported that are capable of promoting PpIX accumulation 
in a cancer specific manner. The combination of MEK inhibitors and 5-ALA could, 
therefore, promote PpIX accumulation to improve the specific fluorescent signal 
intensity for FGS applications, as a strategy to reduce ambiguity of tumour 
margins for the surgeon and to trigger PpIX loading in cancer subtypes that do 
not respond to 5-ALA alone.  
Hypothesis:   Pharmacological inhibition of MEK in combination with 5-ALA will 
promote PpIX fluorescence selectively in cancer cell culture models and animal 
models of cancer. 
Study Objectives: 
Objective 1: To determine the optimal U0126 and 5-ALA dosing paradigm to 
induce PpIX accumulation in a panel of human normal and cancer cell lines 
derived from breast, lung and prostate tissues. 
Objective 2: To determine whether PpIX accumulation is enhanced by the 
combination of U0126 and 5-ALA in 2 mouse models of breast cancer. 
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Figure 4:  PpIX accumulation by MEK inhibitor  
PpIX accumulates significantly more in cancer cells when treated with 5-
ALA+U0126 (MEK inhibitor) compare to only 5-ALA treatment, therefore cancer 
cells emit brighter fluorescent colour which could assist the FGS for tumour 
detection. 
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Chapter 2: Material and methods 
 
2.1 Cell culture  
A panel of human breast, lung and prostate normal and cancer cell lines 
were used in this study. All cell line were purchased from the American Type 
Culture Collection (ATCC). The human breast  cell lines include negative 
(Hs578T, MDA MB 231, MDA MB 468), ER positive (T47D, MCF7, BT474) 
cancer cells and normal breast cells (Hs578-BST) (Table 4) The human lung cell 
lines include non-small lung cancer cell cells (A-549, H460, H1299,H1975) and 
normal lung cell cells (MRC5) (Table 5). The human prostate cell lines include 
androgen-independent (DU145, 22Rv1 and PC3) and androgen receptor-
dependent (LnCaP) cancer cells (Table 6). 4T1 mouse mammary carcinoma cell 
line was obtained from Dr. Jean Marshall (Dalhousie University). Mouse Lewis 
lung carcinoma (LLC) and C3L5 mouse mammary carcinoma cell lines were 
obtained from Dr. Patrick Lee (Dalhousie University) (Table 7). 
 All cell lines used in this study were maintained with high glucose 
Dulbecco's modified Eagle's medium (DMEM) (Invitrogen, 11965-118 Canada), 
supplemented with 10% fetal bovine serum (FBS) (Invitrogen, 12483020, 
Canada), sodium pyruvate (Thermo Fisher Scientific, 11360070, Canada) and 
antibiotic-antimycotic mixture (Invitrogen, 15240062, Canada) (100 Units/ml 
penicillin G sodium) in a humidified atmosphere with 5 % C02 at a temperature of 
37 ºC.  
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Table 4: Human breast cell lines 
Breast cancer 
cell lines 
Origin 
ATTC 
identifier 
Cancer subtype Reference 
Cell plating 
density 
 (cells/ well, 
24 well plate) 
Hs578Bst mammary gland HTB-125 Normal (Hackett et al. 
1977) 
10×104 
BT-474 mammary gland HTB-20 Ductal Carcinoma (Lasfargues, 
Coutinho, and 
Redfield 1978) 
9×104 
Hs578T mammary gland HTB-126 Carcinoma (Hackett et al. 
1977) 
7×104 
MCF7 Pleural effusion HTB-22 Adenocarcinoma (Sugarman et 
al. 1985) 
4×104 
MDA-MB -231 Pleural effusion HTB-26 Medullary 
Carcinoma 
(Brinkley et al. 
1980) 
4×104 
MDA-MB -468 pleural effusion HTB-132 Adenocarcinoma (Brinkley et al. 
1980) 
6×104 
T-47D Pleural effusion HTB-133 Ductal Carcinoma (Judge and 
Chatterton 
1983) 
6×104 
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Table 5: Human lung cell lines  
Lung cancer 
cell lines 
Origin 
ATTC 
identifier 
Cancer subtype  Reference  
Cell plating 
density 
 (cells/ well, 24 
well plate) 
MRC5 Lung CCL-171 Normal (Jacobs, Jones, 
and Baille 
1970) 
5×104 
A549 Lung CCL-185 Carcinoma (Giard et al. 
1973) 
3.2×104 
H460 pleural 
effusion 
HTB-177 large cell lung 
cancer 
(Banks-
Schlegel, 
Gazdar, and 
Harris 1985) 
3.2×104 
H1299 Lymph node CRL-5803 Non-small cell 
lung cancer 
(Giaccone et al. 
1992) 
4×104 
H1975 Lung CRL-5908 non-small cell 
lung cancer 
(Phelps et al. 
1996) 
4×104 
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Table 6: Human prostate cell lines  
Prostate 
cancer cells  
Origin 
ATTC 
identifier 
Cancer subtype Reference 
Cell plating 
density 
 (cells/ well, 24 
well plate) 
DU145 prostate HTB-81 Carcinoma (Papsidero et al. 
1981) 
5×104 
LNCap Prostate CRL-1740 Carcinoma (Gibas et al. 1984) 3.2×104 
PC-3 Prostate CRL-1435 Adenocarcinoma (Kaighn et al. 1979) 5×104 
22Rv1 Prostate CRL-2505 Carcinoma (Sramkoski et al. 
1999) 
3.2×104 
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Table 7: Mouse cancer cell lines  
Mouse 
cancer cell 
line  
Origin 
Mouse 
strain 
ATTC 
identifier 
Cancer subtype Reference 
Cell plating 
density 
 (cells/ well, 
24 well plate) 
C3-L5 Breast  C3H/HeJ 
mice 
 N.A. Carcinoma N.A. 5×104 
LL/2(LLC1) Lung C57BL CRL-1642 Carcinoma (Bertram 
and Janik 
1980) 
3.2×104 
4T1 Breast  Balb/c CRL-2539  
Provided by  
Dr.Jean 
Marshall  
 
Adenocarcinoma (Pulaski et 
al. 2000) 
5×104 
 
*  N.A. – not available  
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2.2      Reagents 
2.2.1 Administration protocol for the MEK inhibitor U0126 
MEK inhibitor U0126 (Cell Signaling Technology, 9903S, USA) was 
dissolved in DMSO (Sigma, D2650, USA) at a stock concentration of 26 mM for 
in vitro and in vivo studies. The stock solution was kept at -80 °C, prepared as 
single thaw aliquots for immediate experimental use. Cultured cells were treated 
with U0126 or DMSO as a diluent control at equivalent percentages to the U0126 
stock. 
2.2.2 Administration protocol for 5-aminolevulinic acid (5-ALA) 
For in vitro studies, monolayer cells were treated with 5-ALA (Sigma, 
A3785, USA) prepared as a sterile stock in serum-free Dulbecco’s Modified 
Eagle Medium (DMEM) (Invitrogen, 11965-118, USA). The 5-ALA stock solution 
(500 mM) was aliquoted in small volumes and kept at -80 °C with immediate 
experimental use after a single freeze-thaw cycle. For in vivo studies, mice were 
injected intratumourally (it), intraperitoneally (ip) or intravenously (iv) with 5-ALA 
in sterile saline (0.85% NaCl, Hospira, 04888010, Canada) to achieve 200 mg/kg 
body weight (BW) per mouse. 
2.3 Effects of MEK inhibition on PpIX accumulation in vitro  
Cells were plated in 24 well plates at the cell density indicated in Table 
4,5,6,7 and incubated overnight to reach 60-70 % confluence. The medium was 
replaced with fresh medium containing U0126 (5, 10 or 20 µM) or control vehicle 
DMSO (1%) as a diluent control at 1, 5, 10 or 20 h before sampling. 5-ALA (500 
mM) was added to the supernatant at 5 h before sampling to achieve a final 
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concentration of 5mM. At the end of the desired experimental time point, cells 
were washed once with ice cold PBS and then lysed with 100 µl of 
radioimmunoprecipitation assay (RIPA) buffer (PBS pH 7.4, NP-40 1% (Sigma, 
MFCD02100484, USA), 0.1% sodium dodecyl sulfate (SDS) (Bio-Rad, 1610302, 
Canada) 0.5 % sodium deoxcycholate (Sigma, 302-95-4, USA). The cell lysates 
were centrifuged at 11,000 x g for 10 min at 4 °C. The supernatant was 
transferred to a clean tube and stored at -80 °C. Cell lysates were diluted in PBS 
(1:30) and PpIX fluorescence was measured using a Modulus Microplate Reader 
(Promega BioSystems, USA), with a 450 nm excitation/635 nm emission filter. 
 
2.4 Effect of MEK inhibition on PpIX accumulation in vivo  
2.4.1 Mouse strains and animal housing  
 
Balb/c inbred female mice were obtained from Charles River Labs and 
transgenic mice of the FVB.Cg-Tg(WapHRAS) 69Lln Chr YSJL/J strain (hereafter 
referred to as HRAS) were imported from The Jackson Laboratory (JAX Mice 
Stock # 002409). A unqiue feature of the transgenic mammary tumour model is 
the incorporation of the human RAS (Harvey rat sarcoma viral oncogene 
homolog) oncogene on to the male Y chromosome, such that male mice 
expressing HRAS under the mammary tissue-specific Whey acidic protein (Wap) 
promoter develop benign adenocarcinomas between 6 to 8 wks of age (Andres 
et al. 1987).  
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All mice were housed in isolated ventilated caging units with Bed-O-Cobs 
bedding (The Andersons Inc, Maumee OH) and suitable enrichment; cages were 
kept within the specific-pathogen-free barrier at the central animal care facility in 
the Health Sciences Centre at Memorial University of Newfoundland. Animal care 
protocols were approved by the Institutional Animal Care Committee, in 
accordance with Canadian Council on Animal Care guidelines. Mice were fed 
with Laboratory Rodent Diet 5010 food (27.5 % protein, 13.5 % fat, 59 % 
carbohydrate; OM Nutrition International, Richmond, IN) with sterile water ad 
libitum, and were housed under a 12:12 hour light/dark cycle.  
2.4.2 Transplanted mammary tumour model (4T1)  
 
Mouse mammary carcinoma 4T1 cells grown as a monolayer in a 10 cm culture 
dish were trypsinized and washed 3x in PBS. Female mice aged 8 wk of age 
were injected with 5x105 cells in 100 µl PBS subcutaneously into the right hind 
flank. After the development of palpable tumours (5-8 mm in diameter) in 10 
days, the mice were injected intratumourly or intraperitoneally with U0126 (19 
mg/kg BW in 100 µl of DMSO/PBS) with an incubation time of 5 or 8 h prior to 
intraperitoneal injection with 5-ALA (200 mg/kg BW in 200 µl saline) 2 h before 
sacrifice. Animals were kept in their home cages and maintained in a darkened 
room prior to sacrifice in consideration of 5-ALA induced photosensitivity. All 
animals were euthanized by CO2 prior to tissue collections. 
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2.4.3 Spontaneous transgenic mammary tumour model (HRAS) 
 
Male HRAS mice bearing mammary tumours at approximately 3 months of 
age were used to determine promotion of PpIX accumulation in the tumours by 
U0126 treatment. Tumour sizes varied from 2-10 mm in a diameter, distributed 
across the mammary tumour chain, but primarily in the ventral, thoracic region. 
Mice were injected intraperitoneally with U0126 (50 µM/kg) in 100 µl DMSO 
(40%)/PBS for treatment group and DMSO (40 %/PBS) control group for 5 h. All 
animals were administered a tail vein injection of 5-ALA solution to achieve a final 
dose of (200 mg/ kg BW in 100 µl saline) 1 h prior to sacrifice. Male mice were 
kept in their home cages and maintained in a darkened room, as described for 
the 4T1 subcutaneous implant tumours. 
2.4.4 Mammary tumour homogenization  
 
All mice carrying implanted or spontaneous tumours were euthanized with 
CO2 gas in a designated chamber. Tumours were then removed carefully to 
avoid non-tumour tissues and rinse with PBS to remove excess blood and 
homogenized in RIPA buffer (300 µl). The tumour homogenate was centrifuged 
at 4C, 14,000 rpm for 10 min to collect intracellular supernatant for the protein 
assay and PpIX fluorescence assay, as described in Section 2.3.  
2.4.5 Protein assay and PpIX measurement of in vivo tumour samples 
 
The protein concentrations of intracellular supernatant were measured 
using a bicinchoninic acid (BCA) protein assay kit (Thermo Scientific, PI23227, 
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USA) according to the manufacturer’s protocol. The colorimetric quantification of 
BCA assay was conducted using a spectrophotometer (Beckman Coulter DU® 
530) at 562 nm. PpIX fluorescence in a complementary aliquot of the matched 
intracellular supernatant was measured as described in section 2.3. PpIX 
fluorescence was standardized to protein concentration of each tumour samples. 
The values are shown as relative fluorescence units (RFU) per microgram of 
protein. 
2.4.6 Fluorescence imaging of PpIX-labelled mammary tumours 
 
Mammary tumours were illuminated with blue light (380–440 nm) 
generated by a D-light system (Storz GmbH, Tuttlingen, Germany) along a 
flexible fibre optic cable held 5-10 cm above the tissue specimen to excite PpIX 
fluorescence.  Digital images were taken with a Canon 6D camera, fitted with a 
36 mm lens and a yellow 635 nm emission lens filter.  
2.5 Statistical analysis 
One way ANOVA with Tukey’s post-hoc test or Student’s t test were 
performed using GraphPad Prism 4.0c software (GraphPad Software, La Jolla, 
CA, USA). 
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Chapter 3: Results 
3.1 MEK inhibition promotes PpIX accumulation in a cancer specific 
manner    
3.1.1    Promotion of PpIX accumulation by MEK inhibition in human normal 
and breast cancer cell lines 
To determine if MEK inhibition promotes accumulation of PpIX 
fluorescence selectively in cancer cells, we compared the combination of a MEK 
inhibitor (U0126) and 5-ALA in the human immortalized breast cell line 
Hs578BST and the breast cancer cell line Hs578T, both of which were derived 
from the same patient (Hackett et al. 1977). Cells were treated with U0126 (20 
µM) or an equivalent percentage of DMSO for 1,5,10, 20 h, with 5-ALA (5mM) 
added 5 h prior to cell lysis. PpIX fluorescence in the lysates was measured 
using a fluorescent microplate reader (excitation ʎ 450 nm; emission ʎ 635 nm) 
(Figure 4A, 4B). There was no significant change in PpIX accumulation in 
immortalized Hs578BST breast cells treated with MEK inhibition for 1, 5, 10 or 20 
h (Figure 4A). On the other hand, accumulation of PpIX fluorescence was 
significantly promoted in breast cancer Hs578T cells treated with 5-ALA plus 
U0126 for 5, 10 or 20 h, as compare to those treated with 5-ALA plus DMSO 
(Figure 4B). As the highest promotion was observed at 20 h after U0126 
treatment, this time point was pursued in subsequent experiments. 
   
Figure 5: Cancer specific promotion of PpIX by MEK inhibition 
Human breast immortalized (Hs578Bst) (A) and cancer (Hs578T) (B) cells 
were treated with MEK inhibitor U0126 (20 µM) or DMSO for 1, 5, 10 and 20 h, 
with 5-ALA (5 mM) initiated 5 h prior to cell lysis in all the treatment groups. PpIX 
fluorescence was measured by a fluorescent microplate reader.  Minimum of 3 
independent experiments were performed with quadruplicate wells for each 
condition. The graphs represent the average of one of the experiments. 
Statistical analyses performed using student’s t test. * p < 0.01. 
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3.2     Promotion of PpIX accumulation by MEK inhibition in different types 
of cancer cell lines.  
3.2.1    Human breast cancer cell lines 
 To determine whether PpIX fluorescence enhancement with the 
combination of MEK inhibitor and 5-ALA is a generalizable phenomenon, we 
compared the PpIX fluorescence response of a panel of human breast cancer 
cells to U0126 plus 5-ALA. The human immortalized breast cell line (Hs578-BST) 
and 6 additional human breast cancer cell lines (BT474, Hs578-T, MCF7, 
MDAMB231, MDAMB468 and T47D) were treated with U0126 (20 µM) or DMSO 
for 20 h, with 5-ALA (5 mM) administered to the culture medium 5 h prior to cell 
lysis (Figure 5A). PpIX accumulation was significantly promoted in 4 human 
breast cancer cell lines, Hs578T, MDA MB 231, T47D, and MCF7. On the other 
hand, no significant change in PpIX accumulation was induced by MEK inhibition 
in 2 breast cancer cell lines (MDA MB 468 and BT474) with this dosing paradigm, 
similar to the immortalized breast cell line Hs578-BST. 
3.2.2 Human lung cancer cell lines 
Four human lung cancer cell lines (A549, H460, H1299 and H1975) and 
the immortalized human lung cell line (MRC5) were used to determine whether 
MEK inhibition promotes PpIX accumulation in the presence of 5-ALA (Figure 
5B). PpIX accumulation was significantly promoted by MEK inhibition in 3 lung 
cancer cell lines treated with 5-ALA (A-549, H460 and H1299) while there was no 
44 
 
significant change in 5-ALA stimulated PpIX fluorescence induced by U0126 
treatment in the lung cancer cell line (H1975) and the immortalize lung cell line 
(MRC5).   
3.2.3 Human prostate cancer cell lines 
The promotion of PpIX accumulation by MEK inhibition plus 5-ALA was 
examined in 4 prostate cancer cell lines (U1456, LNCap, PC3 and 22Rv1) 
(Figure 5C). A significant increase in PpIX fluorescence was observed in DU145 
and LnCaP prostate cancer cell lines. On the contrary, no significant change in 
PpIX fluorescence was observed following U0126 plus 5-ALA combined 
treatment in 22Rv1 or PC3 prostate cancer cells. 
Overall, MEK inhibition increased PpIX accumulation in 4/5 breast cancer 
cell lines, 3/4 lung cancer cell lines and 2/4 prostate cancer cell lines, but had no 
effect in the 2 immortalized cell lines originating from normal human tissues.  
These results suggest that MEK inhibition promotes PpIX accumulation in a 
cancer-specific manner, but some cancer cell lines in the different subtypes 
evade this up-regulation in fluorescence.  
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Figure 6: Promotion of PpIX accumulation by MEK inhibition in human 
breast, lung and prostate cancer cells 
Human breast (A), lung (B) and prostate (C) cell lines were plated in a 24 
well plate. After 24 h, the cells were treated with MEK inhibitor U0126 (20 µM) or 
DMSO for 20 h and 5-ALA (5 mM) for 5 h prior to cell lysis. PpIX fluorescence 
was measured by a fluorescent microplate reader.  A minimum of 3 independent 
experiments were performed with quadruplicate wells for each condition. The 
graphs represent the average of one of the experiments. Statistical analyses 
performed using student’s t test.  * p < 0.01. 
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3.3     Promotion of PpIX accumulation by MEK inhibition in in vivo cancer 
models  
3.3.1 Screening of mouse cancer cell lines in vitro 
To conduct in vivo studies for the combination of MEK inhibition and 5-
ALA on PpIX fluorescence, it was first necessary to identify a mouse cancer cell 
line in which 5-ALA-induced PpIX accumulation is promoted by U0126 treatment. 
Two mammary cancer cell lines (C3-L5 and 4T1) and a lung cancer cell line 
(Lewis lung carcinoma (LLC)) were treated with or without U0126 (20 µM) for 20 
h and then with 5-ALA (5mM) for 5 h.  PpIX accumulation was significantly 
increased by U0126 treatment in all the mouse cancer cell lines tested (Figure 
6A). Among the cell lines, 4T1 cell lines showed the highest fold change with 
MEK inhibition plus 5-ALA.  To confirm the optimal time course for promotion of 
PpIX accumulation by MEK inhibition in the 4T1 line, the cells were treated with 
U0126 (20 µM) for different durations (1, 5, 10 and 20 h), keeping 5-ALA 
exposure consistent at 5 h prior to cell lysis (Figure 6B).  Similar to the human 
breast cancer cell line Hs578T, PpIX fluorescence was significantly promoted in 
4T1 cells treated with U0126 for 5, 10 or 20 h, compare to those treated with 
DMSO (1 %). Based on these results, the mouse breast 4T1  tumour model was 
used for xenograft tumours in the animal studies, with a dosing protocol that 
provides U0126 several h prior to the administration of 5-ALA.  
 
   
Figure 7: Promotion of PpIX accumulation by MEK inhibition in mouse 
cancer cell lines  
 
Mouse breast cancer, C3L5 and 4T1, and mouse lung cancer, LLC, were 
plated in 24 well plates.  (A) After 24 h, the cells were treated with MEK inhibitor 
U0126 (20 µM) or DMSO for 20 h and 5-ALA (5 mM) for 5 h prior to cell lysis. (B) 
4T1 cells were treated with MEK inhibitor U0126 (20 µM) or DMSO for 1, 5, 10 
and 20 h, and 5-ALA (5 mM) for 5 h prior to cell lysis. PpIX fluorescence was 
measured by a fluorescence microplate reader.  A minimum 3 independent 
experiments were performed with quadruplicate wells for each condition. The 
graphs represent the average of one of the experiments. Statistical analyses 
performed using student’s t test.  * p < 0.01.
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3.4 PpIX accumulation by U0126 MEK inhibition in vivo 
3.4.1 In vivo: Mouse 4T1 breast tumour model 
To determine the efficacy of U0126 treatment on promotion of PpIX 
accumulation in vivo, 4T1  tumours were established in the hind flank of age-
matched and BW-matched female BALB/c mice (n=18) by injection of 5x105 cells 
and follow up for tumour growth over a period of 10 days. Optimal tumour size for 
experimental use was 5-10 mm. The mice were divided into three groups:  a 
control group that received intra tumoural injection of DMSO/saline (40% DMSO) 
for 8 h (n = 6 mice), a U0126 treatment group that received intra tumoural (it) 
injection of U0126 (50 µM/kg) in 250 µl Saline/PBS for 5 h prior to sacrifice (n = 6 
mice) and a U0126 treatment group that received it injection of U0126 (50 µM/kg) 
in 250 µl Salin/PBS 8 h prior to sacrifice (n = 6 mice).  All three groups received 
5-ALA (200 mg/kg BW) by intraperitoneal injection (ip) injection 2 h before 
sacrifice.  The mice were sacrificed with CO2 gas and the tumours were removed 
and homogenized. The amount of PpIX accumulation was determined as 
described in section 3.1.1.  As shown in Figure 7A, the mean PpIX fluorescence 
was higher in the tumours of mice treated with 5-ALA plus U0126 for either 5 or 8 
h, as compare to those treated with 5-ALA plus DMSO/saline; however, PpIX 
fluorescence was statistically promoted (2.5 fold) only in the tumours of mice 
treated with U0126 for 8 h prior to the 5-ALA injection 2 h before sacrifice.  
To further confirm the results of the promotion of PpIX accumulation by it 
injection, it was determined whether a different route of U0126 injection, ip 
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injection, was also effective using the same in vivo tumour model.  BALB/c mice 
bearing 4T1 tumours were again divided into three groups, as per the it injection 
experiments: a control group that received ip injection of DMSO/saline (40%) (n = 
6 mice), a treated group that received U0126 by ip injection (50 µM/kg) for 5 h 
prior to sacrifice (n = 6 mice) and a treated group that received U0126 by ip 
injection (50 µM/kg) for 8 h prior to sacrifice (n = 6 mice) (Figure 7B).  All three 
groups received 5-ALA (200mg/kg BW) by intraperitoneal injection (ip) injection 2 
h before sacrifice. PpIX fluorescence was significantly increased (2.5) in the 
tumours of mice treated with 5-ALA plus U0126 for 5 h, but not in those treated 
with 5-ALA plus U0126 for 8 h, as compare to those treated with vehicle control 
(DMSO) and 5-ALA alone.  
3.4.2 In vivo: H-Ras transgenic mouse model 
To determine whether MEK inhibition is effective to promote PpIX 
accumulation in spontaneous mammary tumours, the H-Ras transgenic mouse 
model of mammary cancer was investigated with the 5-ALA and U0126 drug 
combination.  Mice at age 3 months with tumours ranging in size from 2-10 mm in 
a diameter, were divided into 2 treatment groups:  a control group that received ip 
injection of DMSO/saline (40%) (n = 13 mice) 5 h before sacrifice, and the U0126 
group received ip injection of U0126 (50 µM/Kg) (n = 13 mice) 5 h prior to 
sacrifice. Both groups received 5-ALA (200 mg/kg BW) by tail vein injection at 1 h 
before sacrifice, according to a published protocol (Dorward et al. 2005). PpIX 
fluorescence in the tumours was measured as described in section 3.1.1. PpIX 
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accumulation was significantly increased (2-3 fold) in the tumours of mice treated 
with 5-ALA plus U0126 when compare to those treated with 5-ALA and the 
vehicle control (DMSO) (Figure 8). These results demonstrate that treatment of a 
MEK inhibitor prior to 5-ALA exposure increases PpIX accumulation in vivo when 
the mammary tumours arise spontaneously.   
 
   
 
Figure 8: Promotion of PpIX accumulation by MEK inhibition in 4T1 
mammary tumour models  
 
Mouse breast cancer 4T1 cells were grown to 80% confluency and 
suspended in PBS. Subsequently, 5x105 cells/100µl 4T1 cells were injected in 
the right hind flank of eight week old, female BALB/c mice. After the development 
of visible tumours (5-8 mm in diameter), the mice were injected it (A) or ip (B) 
with U0126 (50 µM) for 5 or 8 h, or DMSO for 8 h, and ip with 5-ALA (200 mg/kg 
BW) for 2 h. Tumours were isolated for tissue homogenization and PpIX 
accumulation was determined by fluorescence microplate readings. (A:  n = 6 
mice per group; B:  n = 10 mice per group) 
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Figure 9: Promotion of PpIX accumulation by MEK inhibition in H-Ras 
transgenic mice 
 
HRAS mice bearing mammary tumours at 3 months size range between 2-
10 mm in diameter. Mice were injected ip with U0126 (50 µM/kg in 100 µl 
DMSO/PBS), or DMSO/PBS alone, 5 before sacrifice. All mice were administered 
a tail vein injection of 5-ALA solution to achieve a final dose of 200 mg/ kg BW 
(100 µl saline) 1 h prior to sacrifice (n = 13 mice per group). 
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3.4.2 In vivo tumour imaging by PpIX fluorescence  
In the clinical setting, PpIX fluorescence is used for surgical guidance to 
distinguish tumours from normal tissue. Having measured increased 
fluorescence in isolated tumour lysates with the combination of U0126 and 5-
ALA, we examined whether treatment of the MEK inhibitor in vivo can enhance 
the fluorescence visibility of mammary tumours in mice. Balb/c mice bearing 4T1  
tumours were injected IP with DMSO/saline for 5 h (Control), with DMSO/saline 
for 5 h plus 5-ALA for 2 h (5-ALA+DMSO) or with U0126 for 5 h and 5-ALA for 2 
h (5-ALA+U0126) (Figure 9). PpIX fluorescence images were taken with Canon 
6D digital camera with 35mm lens under blue light (380–440 nm). As shown in 
Figure 9, 5-ALA treatment induced PpIX fluorescence within the tumours while no 
PpIX fluorescence was observed in the tumours without 5-ALA injection 
(Control).  Moreover, 5-ALA treatment combined with U0126 (5-ALA+U0126) 
showed enhanced PpIX fluorescence in the tumour compare to 5-ALA only 
treatment (5-ALA+DMSO). The combination treatment for the spontaneous 
HRAS transgenic mammary tumours was similarly imaged in untreated, 5-ALA 
treated or 5-ALA+U0126 treated animals. Like the 4T1 grafted tumour model, 
enhanced PpIX fluorescence was visible in the isolated tumours, both to the eye 
and the camera fitted with the emission filter (Figure 10). These results further 
demonstrate the practical value for in vivo promotion of PpIX fluorescence by 
MEK inhibition and the potential for improved tumour contrast during FGS. 
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Figure 10: Real time visualization of PpIX accumulation by MEK inhibitor in 
4T1 tumours 
 
Mammary 4T1 Tumour were illuminated with blue light (380–440 nm) 
generated by a D-light system (Storz GmbH, Tuttlingen, Germany) to excite PpIX 
fluorescence. Digital images were taken with a Canon 6D camera with 36 mm 
lens that was fitted with a yellow 635 nm emission filter.  
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Figure 11: Real time visualization of PpIX accumulation by MEK inhibitor in 
HRAS tumours 
 
HRAS mammarye tumour were illuminated with blue light (380–440 nm) 
generated by a D-light system (Storz GmbH, Tuttlingen, Germany) to excite PpIX 
fluorescence. Digital images were taken with a Canon 6D camera with 36 mm 
lens that was fitted with a yellow 635 nm emission filter.  
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Chapter 4: Discussion 
4.1 General Discussion 
 
Fluorescence-guided resection of tumours is a novel approach for the 
surgical management of cancer patients. Although PpIX fluorescence is the most 
commonly used method for fluorescence-guided resection, insufficient PpIX 
accumulation often limits its benefit in certain types of tumours (Wang et al. 
2013). Therefore, the objective of my research project was to determine if 
modulation of cell signalling pathways promotes PpIX accumulation induced by 
5-ALA treatment in cancer cell lines and animal models of cancer.     
The selection of the signalling pathway to target was influenced by a prior 
finding in Dr. Hirasawa’s laboratory, where a novel interaction was noted 
between the heme biosynthesis and the oncogenic Ras/MEK pathways. In a cell 
culture model, it was found that pharmacological inhibition of MEK in transformed 
mouse fibroblast cells that have constitutively up-regulated RAS/MEK signalling 
activity led to promotion of PpIX accumulation induced by 5-ALA treatment 
(unpublished data). To validate this result, they examined human normal and 
cancer cells to determine whether PpIX accumulation can be promoted in human 
cell lines with the same drug combination. They concluded in this pilot 
experiment, that PpIX accumulation was promoted by MEK inhibition in human 
cancer cells but not in normal cells (unpublished data), which is a necessary 
requirement for FGS applications. To build on these promising results, my MSc 
project objectives were to determine: 1) whether MEK inhibition promotes PpIX 
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accumulation in different subtypes of cancer, and 2) whether MEK inhibition 
promotes PpIX accumulation in mouse models of breast cancer.  
4.2 In vitro experimental models 
To investigate the generalizability of PpIX promotion using the drug 
combination of 5-ALA plus the MEK inhibitor U0126, an expanded screening 
panel of human normal and cancer cells were selected, including breast, lung 
and prostate cancer cells. I found that MEK inhibition leads to enhanced PpIX 
accumulation in 4 of 6 breast cancer cell lines examined (Hs578-T, MDA MB 231, 
T47D, and MCF7), but not in BT474 and MDA MB 468 cells. Previous studies 
have examined a selection of this breast cancer cell line panel for PpIX 
accumulation in culture, including MCF7 and MDA MB 231. Similar to our study, 
these breast cancer cell lines showed enhanced PpIX fluorescence above the 
normal “immortalized” cell line MCF10A after 5-ALA treatment (Millon et al 2010). 
Our study is the first to show enhanced PpIX loading with the combination of 5-
ALA and U0126 in breast cancer cell lines, which may have clinical value for FGS 
in breast cancer (Frei et al. 2004; Vahrmeijer et al. 2013; Ladner et al. 2001).  
Enhanced PpIX accumulation was also observed in 3 of 4 lung cancer cell 
lines (A549, H460, H1299) but not in H1975 cell line. PpIX loading was also very 
high with 5-ALA alone in H1975, suggesting a limit to the potential for 
improvement with U0126 addition (data not shown). As per our findings, a 
previous study has reported PpIX accumulation by 5-ALA treatment in A549 lung 
cancer cells when treated with 5-ALA, but enhanced PpIX with the U0126 
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combination is a novel finding for the lung cancer cell lines we examined, which 
is very promising for FGS applications (Ali et al. 2011).  
 For prostate cancer, the results of our study showed 2 of 4 prostate 
cancer cell lines (DU145, LnCaP) with higher PpIX levels following treatment with 
5-ALA and the U0126 MEK inhibitor, but no enhancement observed in PC-3 or 
22Rv1 cell lines. One other study reported 5-ALA leads to PpIX enhancement in 
LNCaP cells for the purpose PDT treatment (Ortel et al. 2002). For those two cell 
lines that showed no PpIX enhancement, the expression of the Raf/MEK/ERK 
cascade is reported to be at lower activity levels, which may explain the lack of 
effect of the MEK inhibitor U0126 in these cell lines (McCubrey et al. 2007b). This 
concept could be important for any FGS-personalized medicine strategy, wherein 
culture models or human tumour biopsies are examined for biomarkers of the 
Raf/MEK/ERK activation state, as a predictor of PpIX fluorescence enhancement 
in the presence of 5-ALA. PpIX accumulation wasn’t observed in the two cell 
lines originated from normal prostate tissues (Hs578-BST, MRC5), again 
confirming the specificity of PpIX loading for cancer cells, even in the presence of 
5-ALA plus U0126. These overall results of the cell culture investigations suggest 
that MEK inhibition promotes PpIX accumulation in a broad range of cancer cells 
treated with 5-ALA. 
4.3 In vivo experimental models 
After conducting in vitro experiments using different human cancer cell 
lines, we decided to determine whether PpIX accumulation can be similarly 
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promoted in mammary tumours that were grafted or developed spontaneously in 
mouse models. For the grafting experiments, we first screened three mouse 
mammary cancer cell lines for promotion of PpIX accumulation by MEK inhibition 
and found that promotion of PpIX accumulation by MEK inhibition was highest in 
mouse breast cancer 4T1 cells. Mice bearing 4T1 tumours inoculated on the hind 
flank were subsequently injected it or ip with U0126 and then PpIX accumulation 
in the tumours were measured at 5 and 8 h after injection, incorporating a 1 h 
incubation of an IP 5-ALA dose. We observed significant promotion of PpIX 
accumulation only at 8 h for it injection and at both 5 and 8 h for ip injection of 
U0126. In it injected-mice, we observed internal bleeding within the tumours 
caused by the U0126 injection. As contamination of red blood cells in the tumour 
lysates influences PpIX assay, this may be the reason that the promotion was not 
observed in mice it injected at the earlier time point (5 h). 
In addition to the grafted model of mammary tumour cells, we examined 
whether treatment of MEK inhibitor promotes PpIX accumulation in a more 
heterogeneous population of tumour cells, as reflected by spontaneous 
mammary tumours arising in a transgenic mouse strain. Male mice of the HRAS 
transgenic line develop mammary adenosquamous carcinomas at approximately 
3 months of age, under mammary epithelium driven expression of the Harvey rat 
sarcoma viral oncogene that integrated on Chr Y (Andres et al. 1987). This strain 
was examined in a previous study conducted by Dorward et al (2005), 
establishing significant PpIX accumulation selectively in tumour cells following 5-
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ALA administration. In our study, in vivo MEK inhibition significantly increased 
PpIX fluorescence induced by 5-ALA treatment in the mammary tumours of the 
transgenic males. Our findings in both animals models were consistent, 
supporting enhanced PpIX accumulation with the combination of 5-ALA plus 
U0126, which is a very promising outcome for fluorescence improvements in 
FGS applications. Our in vivo studies warrant further animal and pre-clinical 
studies in the future, to r alternate MEK inhibitors and to further the exploration of 
the mechanism of PpIX enhancement suggested by cell culture models.  
4.4 Possible mechanisms of PpIX accumulation by U0126 MEK inhibitor 
MEK inhibition promoted PpIX accumulation in a cancer specific manner in 
vitro and in vivo. However, the molecular mechanisms of the promotion of PpIX 
accumulation still remain to be studied. Based on literature evidence 
predominantly determined in cell culture systems, there are three suggested 
mechanisms:   
 
1. Downregulation of ATP-binding cassette (ABC) transporter family 
(ABCG2). 
2. Downregulation of ferrochelatase (FECH) activity. 
3. Reduction of cellular pH by MEK inhibition. 
4.4.1 Downregulation of ABCG2 by U0126  
  
ABCG2, a member of protein family of ATP-binding cassette (ABC) 
transporters, serves a cellular function to reduce PpIX accumulation in the 
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mitochondria by regulating its efflux to intracellular environment. Cancer cells 
frequently overexpress ABCG2 and it is notable that the expression level of 
ABCG2 is higher in cancer stem cells and drug-resistant cancer cells (Diestra et 
al. 2002; Jonker et al. 2002; Robey et al. 2005). The role of ABCG2 as a 
chemical transporter is to limit the absorption or re-uptake of drugs and toxins in 
our diet and to maintain intact cellular homeostasis by efflux out potentially toxic 
chemicals or chemotherapeutic drugs. The first study to prove this mechanism 
showed that oral bioavailability of topotecan (Chemotherapy agent) was 
significantly increased in mice treated with an ABCG2 inhibitor (Allen et al. 1999). 
Therefore, ABCG2 is recognized as a biomarker for predicting drug resistance 
cancer cells (Bessho et al. 2006). 
One of the possible mechanisms for promotion of PpIX accumulation by 
MEK inhibition is downregulation of ABCG2 transporter protein expression. Imai 
et al. (2009) reported for human MCF-7 breast cancer cells and NCI-N87 colon 
cancer cells treated with the MEK inhibitor U0126, there was increased 
degradation of the ABCG2 transporter protein leading to increased net 
accumulation of anticancer agents. Another study demonstrated that a MAPK 
inhibitor led to degradation of ABCG2 protein, therefore suggesting that MAPK 
pathway inhibition is a strategy for overcoming ABCG2-mediated multidrug 
resistance in laryngeal squamous cell carcinoma (Xie et al. 2014). These studies 
both support the ABCG2 transporter as a downstream expression target of the 
MEK pathway that is sensitive to signalling pathway activity. Furthermore, 
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overexpression studies implicate the ABCG2 transporter as a primary controller 
of PpIX accumulation. In colon cancer cells (SW480), engineered overexpression 
of ABCG2  reduced 5-ALA induced PpIX fluorescence, both in vitro and in vivo 
(Kim et al. 2015). Similarly, inhibitors of ABCG2 transporter, such as Ko143 
(Asashima et al. 2006) and Elacridar were reported to increase PpIX 
accumulation in cells treated with 5-ALA, as part of a study to examine the role of 
human ABC transporter ABCG2 in photodynamic diagnosis (PDD)(Ishikawa et al. 
2011). These results indicate that PpIX loading is dependent on ABCG2 
expression level. Therefore, downregulation of ABCG2 transporter may be one of 
the mechanisms that underlies the promotion of PpIX accumulation with MEK 
inhibition. ABCG2 inhibitors have received significant attention for the 
development of chemical inhibitors to overcome drug resistance in cancer 
patients; however, the inhibition of ABCG2 transport with these inhibitors is not 
cancer-cell specific, thus undermining the potential benefit of ABCG2 inhibitor to 
increase cancer-specific PpIX loading (To and Tomlinson 2013). 
4.4.2 Downregulation or inhibition of FECH by U0126 
Another possible mechanism by which MEK inhibition could influence 
PpIX accumulation is to influence the enzyme expression and activity of the 
heme synthesis pathway. The heme biosynthetic pathway consists of several 
enzymatic steps (Figure 2). FECH, the terminal enzyme of the pathway, converts 
PpIX into non-fluorescent heme with the incorporation of the iron atom, as one of 
the rate limiting steps for heme synthesis (Olsson et al. 2002). Downregulation of 
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FECH expression is considered to play a major role in the intracellular PpIX 
accumulation (Kemmner et al. 2008). Moreover, low expression of FECH in 
malignant tumours, such as colon cancer and urothelial cancer, is correlated with 
high intracellular PpIX accumulation in tumour cells (Peng et al. 1997). Inhibition 
of FECH by iron chelator deferoxamine (DFX) and NOC-18 through nitric 
generation have been reported to promote cellular PpIX accumulation in 5-ALA-
treated human oral squamous cell carcinoma HSC-4 cells (Yamamoto et al. 
2013). In another study, significant accumulation of PpIX was also observed by 
inhibition of FECH using deferoxamine and NOC-18 in ALA-treated prostate 
cancer PC-3 cells (Fukuhara et al. 2013). Furthermore, silencing FECH by siRNA 
promotes PpIX accumulation in human glioma cell lines SNB19 and U87 
(Kemmner et al. 2008). Finally, the injection of dendritic nanocarriers containing 
FECH siRNA promoted the fluorescence detection of tumours in an animal 
tumour model (Wan et al. 2012). However, there has been no report that 
indicates regulation of FECH activity in influenced by MEK activity. Nevertheless, 
it is still possible that MEK inhibition promotes PpIX accumulation by down- 
regulating FECH.  
4.4.3 Reduction of cellular pH by MEK inhibition  
Several studies have reported that the tumour’s microenvironment may 
lead to PpIX accumulation after 5-ALA administration. In general, pH is lower in 
the tumour external environment compare to normal tissue (Gerweck and 
Seetharaman 1996). Certain enzymes in the heme biosynthesis pathway function 
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optimally at lower pH. For instance, PBG-D at a pH of 6.2-6.4 forms the skeletal 
structure of porphyrinogen (Balgi et al. 2011). A different research group showed 
the enhancement of PpIX after 5-ALA administration by lowering tumour pH with 
Glucose (Piot et al. 2001). In addition, inhibition of RAF-ERK-MEK pathway leads 
to acidic environment in tumour cells.  One study showed that inhibition of ERK-
activating Thr202/Tyr204 phosphorylation by PD98059 in human breast cancer 
MCF-7 cells leads to an extracellular acidic environment of pH 6.2 (Balgi et al. 
2011) which may represent another possibility of PpIX accumulation by U0126. If 
an acidic environment leads to increased PpIX accumulation, inhibition of RAF-
ERK-MEK by U0126 may promote PpIX accumulation indirectly. According to 
these studies combination of outcomes by MEK inhibition could enhance PpIX 
accumulation. All the mechanisms described are not mutually exclusive. 
  
4.5    Compounds that leads to PpIX accumulation  
There are other compounds that are known to promote PpIX 
accumulation in vitro. Here, I will discuss about them in comparison with 
MEK inhibitors.  
4.5.1 ABCG2 inhibitors 
ABCG2 is widely expressed in both normal and cancer cells (G. Zhang et 
al. 2013). According to previous studies,  ABCG2 inhibitors lead to PpIX 
accumulation in short time (60 m) in cancer cells (Asashima et al. 2006) compare 
to MEK inhibitors (10-20 h). However, Hirasawa lab observed that ABCG2 
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inhibitors promote PpIX accumulation in normal cells (Ema Yoshioka 
2015).Therefore, the advantage to use MEK inhibitors over ABCG2 inhibitors in 
the clinical settings is their cancer specificity. This is very important because by 
accumulation of PpIX in normal cells surgeon is unable to distinguish normal cells 
from cancer cells. 
4.5.2 FECH inhibitors 
FECH plays a major role in the final step of heme synthesis as it converts 
protoporphyrin IX (PpIX) to functional heme. Inhibition of FECH leads to increase 
PpIX accumulation. However, increase PpIX levels by FECH inhibition alone is 
often not sufficient to increase PpIX accumulation (Yamamoto et al. 2013). FECH 
inhibitors are required to be treated with other compounds to have significant 
effect on the PpIX accumulation. Therefore, MEK inhibitors may be an ideal 
candidate for the combined treatment.  
4.5.3 Feasibility of MEK inhibitors for use in FGS applications  
 The MAPK pathway is one of the most deregulated signal transduction 
pathways in human cancer. Several MEK inhibitors have been developed and 
evaluated in different clinical studies. One of the MEK inhibitors, Trametinib, has 
been approved for clinical use by the FDA (National Cancer Institute 2016). In 
general, MEK inhibitors are well tolerated in the clinical setting with the most 
common side effects being minor, such as diarrhoea, rash and fatigue.  Given 
that both MEK inhibitors and 5-ALA are already approved for clinical use, the 
combination of a MEK inhibitor and 5-ALA to enhance PpIX in cancer cells would 
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be a feasible idea for FGS applications. There are several possible advantages 
from this drug combination, in addition to improved FGS sensitivity: 1) MEK 
inhibitors have independent antitumour effects and could, therefore, act additively 
or synergistically with anti-cancer effects when patients are treated with PDT or 
chemotherapy;  2) potential reduction of 5-ALA dosing to reduce the side effects 
of peripheral nerve pain and burning sensations when patients treated with 5-
ALA are exposed to light; (Kemmner et al. 2008). 3) MEK inhibitors have the 
potential to enhance the efficiency of chemotherapeutic drugs by inhibiting the 
efflux of the drug out of the cell through an ABCG2-directed mechanism. 
 
 
4.6 Conclusion  
1) The promotion of PpIX accumulation by MEK inhibition enhanced PpIX 
accumulation in certain cancer cell models (breast, lung, prostate) in this 
study. On the other hand, there were cancer cell lines in which PpIX 
accumulation was not observed along with two normal immortal cell lines. It 
is important to investigate the molecular mechanism of PpIX accumulation to 
overcome the resistant cellular population. This study shows the cancer 
specificity of PpIX accumulation by MEK inhibitor which is very important in 
FGS to distinguish normal tissue from tumours. 
2) The MEK inhibitor demonstrated its ability to promote PpIX accumulation 
in in vivo cancer models Based on the results, I believe that MEK inhibitors 
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have a great potential to improve visualization of tumour fluorescence, which 
support the tumour resection in the clinical settings. 
4.7 Future Directions 
1) Identification of which molecule of the heme biosynthesis pathway is 
regulated by Ras/MEK.  
The heme biosynthesis pathway is regulated by several enzymes such as 
delta aminolevulinic acid synthase (ALAS), ALA dehydratase (ALAD), 
porphobilinogen deaminase (PBGD), uroporphyrinogen-III synthase (UROS), 
uroporphyrinogen decarboxylase (UROD), prophyrinogen oxidase (CPO) and 
protoporphyrinogen oxidase (PPO) (Figure 2). Activation of these enzymes 
promotes accumulation of PpIX. In contrast, ferrochelatase (FECH)-mediated 
insertion of iron into PpIX and ATP-binding cassette sub-family G-2(ABCG2) 
transport activity both reduce the fluorescent PpIX pool within the cell. FECH 
activity can be measured using the method described by van Hillegeresberg 
in absence or presence of a MEK inhibitor (Kemmner et al. 2008).  
Furthermore, the expression levels of these enzymes can be determined in 
human cancer cells treated with or without U0126 by Western blot analysis 
and qRT-PCR. 
2) Determine whether the MEK inhibitors are effective to enhance 
visualization of metastatic foci in animal models.  
FGS can be used to remove metastatic foci in clinical settings. I believe that 
combined treatment of 5-ALA with MEK inhibitor would improve the detection 
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of metastatic foci. To determine this, metastatic mouse cancer models will be 
established by iv injection of a metastatic cancer cells line. Mice will be 
treated ip with 5-ALA and with Selumetinib (50/100 µM). The visualization of 
metastatic foci will be evaluated by whole body imaging analysis. The lungs 
will be removed and tumour fragments isolated for tissue homogenization to 
determine PpIX accumulation by microplate fluorescence readings.  
3) Determine whether combination of the MEK inhibitor and 5-ALA leads 
to more effective FGS of brain tumours.  
High grade gliomas are extremely aggressive and, despite of different options 
for treatment, the prognosis is poor.  Although complete resection of 
malignant glioma is essential for patient’s survival, it is difficult to be achieved 
as the margins between tumours and normal tissues are unclear. Therefore, 
gliomas are the type of cancers where a significant improvement of FGS 
techniques are needed most. Therefore, it is critical to determine whether 
MEK inhibitor could improve tumour visualization in mouse glioma models. 
Mice implanted with glioma tumours will be treated ip with 5-ALA and with 
Selumetinib (50/100 µM). The visualization of the brain will be evaluated by 
live imaging analysis to determine PpIX accumulation.   
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